<DOC>
	<DOC>NCT00647049</DOC>
	<brief_summary>The purpose of this study is to determine whether combined chemotherapy [rituximab plus high dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max. 2 cycles) followed by high dosage carmustin/thiotepa] followed by peripheral blood stem cell transplantation is effective in the treatment of cerebral Non Hodgkin lymphoma [PCNSL].</brief_summary>
	<brief_title>Freiburg ZNS-NHL Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>group A: first diagnosis of PCNSL, histologically confirmed group B: relapse or progression of PCNSL after MTX containing chemotherapy age 18 65 years not legally incompetent, physically or mentally incapable of giving consent written signed and dated informed consent of the legal representative and if possible of the patient manifestations of further lymphoma outside the CNS seropositive for HIV severe pulmonary, cardiac, hepatic, renal impairment neutrophil count &lt; 2.000/µl, platelet count &lt; 100.000/µl pulmonary disease with IVC &lt; 55%, DLCO &lt; 40% cardiac ejection fraction &lt; 50%, uncontrolled malign arrhythmia creatinine &gt; 1,5 mg% or creatinineclearance &lt; 50ml/min bilirubin &gt; 2mg/dl ascites or pleural effusion (&gt; 500ml) pregnancy o r lactation women with childbearing potential without sufficient contraception participation in another clinical trial within the last 30 days prior to the begin or parallel to this study known or current drug or alcohol abuse known hypersensitivity against methotrexate, cytarabine, thiotepa, BCNU rituximab, leukovorin, dexamethasone, neupogen and neulasta.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>